http://ift.tt/eA8V8J
The battle between Amgen and Regeneron over the patent for a new cholesterol drug continues. An appeals court hearing yesterday has Regeneron hoping to overturn a lower court ruling that favored its rival. One analyst handicaps an Amgen victory at 55%. But win or lose, there are problems on the horizon.
June 07, 2017 at 08:44PM
from Johanna Bennett
No comments:
Post a Comment